Nyxoah’s Q4 and FY2024 Financial and Operating Results: A Look into the Company’s Progress in Neuromodulation for Obstructive Sleep Apnea
Nyxoah SA, a pioneering company specializing in the development of innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation, recently reported its financial and operating results for the fourth quarter and fiscal year 2024. The company’s progress in this area is noteworthy as it continues to pave the way for breakthrough solutions to address this prevalent condition.
Financial Highlights
The fourth quarter of 2024 saw revenue of €1.5 million ($1.7 million) for Nyxoah, marking a significant increase compared to the same period in the previous year. The company’s total revenue for the fiscal year 2024 reached €3.3 million ($3.8 million), demonstrating consistent growth.
Operational Highlights
Nyxoah’s progress extends beyond financial achievements as it continues to make strides in the regulatory approval process for its flagship product, the Gentherm SleepPro® System. The FDA’s PMA application review is nearing conclusion, with the Company anticipating a decision in the first half of 2025.
Impact on Individuals
For individuals diagnosed with OSA, the potential commercial launch of the Gentherm SleepPro® System in March 2025 represents a significant opportunity. This non-invasive, drug-free treatment alternative could offer relief to millions of people who suffer from this condition, allowing them to improve their sleep quality and overall health.
Impact on the World
OSA affects approximately 1 billion people worldwide, and the current treatment landscape is limited. The introduction of the Gentherm SleepPro® System could revolutionize the way OSA is managed, especially for those who cannot tolerate or are not responsive to existing therapies. This innovative approach to neuromodulation could lead to improved patient outcomes, reduced healthcare costs, and a better quality of life for millions of individuals.
Conclusion
Nyxoah’s financial and operating results for the fourth quarter and fiscal year 2024 represent a strong foundation for the company’s continued growth in the field of neuromodulation for the treatment of Obstructive Sleep Apnea. With the FDA PMA application review nearing conclusion and a commercial launch anticipated in March 2025, the potential impact on individuals and the world is significant. The Gentherm SleepPro® System offers a non-invasive, drug-free treatment alternative that could revolutionize the way OSA is managed, ultimately improving the lives of millions of people.
- Nyxoah reported revenue of €1.5 million ($1.7 million) in Q4 2024, up from the same period in the previous year.
- Total revenue for FY2024 reached €3.3 million ($3.8 million).
- FDA’s PMA application review for the Gentherm SleepPro® System is nearing conclusion, with a decision anticipated in H1 2025.
- The potential commercial launch of the Gentherm SleepPro® System in March 2025 could offer relief to millions of people diagnosed with OSA.
- The impact of this innovation could lead to improved patient outcomes, reduced healthcare costs, and a better quality of life for millions of individuals.
